Gilead Provides Update on U.S. Indication for Trodelvy® in …
2 days ago · Back. Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing ...
Gilead withdraws bladder cancer drug in US after failed trial
1 day ago · GILD. (Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a ...
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
2 days ago · By Frank Vinluan on October 18, 2024. Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that ...
Gilead withdraws Trodelvy in bladder cancer after trial flop
1 day ago · However, the bladder cancer flop came on the back of another more important trial failure, in which Trodelvy failed to move the needle in second-line non-small cell lung cancer (NSCLC) when pitted ...
Gilead withdraws Trodelvy in bladder cancer | BioPharma Dive
2 days ago · Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following negative trial results. The FDA granted Trodelvy accelerated approval for bladder cancer in 2021, based on results that found it shrank tumors in people whose disease ...
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial …
1 day ago · The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead is withdrawing Trodelvy from the market in bladder cancer after a confirmatory study did not meet its primary endpoint.
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in …
1 day ago · Gilead Sciences is pulling its blockbuster breast-cancer drug Trodelvy from use in certain patients with bladder cancer following the failure of a confirmatory study. Gilead on Friday said it ...
Gilead's Trodelvy approved in metastatic urothelial cancer
5 days ago · Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.
U.S. FDA Grants Accelerated Approval to Trodelvy for the …
Apr 13, 2021 · An estimated 83,000 Americans will be diagnosed with bladder cancer in 2021, and almost 90% of those diagnoses will be UC. The relative five-year survival rate for patients with metastatic UC is 5.5%.
Gilead and Merck Announce Phase 2 Data Showing a ... - Business …
15 hours ago · Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a P ... viral hepatitis, COVID-19, cancer, and ...
- Some results have been removed